Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
- Japan PM Announces Yen-Loan Program to Fight Pandemics
September 25, 2023
- Ex-Minister Tamura Tapped for No. 2 in LDP Policy Panel
September 25, 2023
- METI to Bankroll 95.5 Billion Yen in 23 Projects to Build Vaccine Sites, Moderna Among Them
September 22, 2023
- MHLW Panel Members Call for Tightening Advertising Regulations for Off-Label GLP-1 Use
September 22, 2023
- Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
- Chuikyo Rep Grumbles at Too Many Industry Requests, FPMAJ Chief Wants Health Coverage Dabate
September 21, 2023
- Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Launches Fall COVID-19 Vaccination Campaign
September 21, 2023
- Apply Brand-Based Price Revisions to Qualified Generic Makers: JGA
September 21, 2023
- JPWA Urges Price Hikes for Drugs with NHI Tag Below 20 Yen
September 21, 2023
- MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
- 10-20% of Infected Adults Suffer Long COVID: MHLW Study
September 20, 2023
- Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
- Hamachi, Miyazaki Named Senior Vice Health Ministers
September 19, 2023
- Health Minister Set to Visit Boston Life Sciences Cluster
September 19, 2023
- Opposition Party Leader Raps Takemi’s Appointment as Health Minister
September 19, 2023
- Japan Grants Orphan Tag to Tafinlar/Mekinist, Retevmo
September 19, 2023
- Japan to Require Out-of-Pocket Cost for COVID Drugs from October
September 19, 2023
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…